Sector
PharmaceuticalsOpen
₹89.23Prev. Close
₹85Turnover(Lac.)
₹0.3Day's High
₹89.23Day's Low
₹82.0152 Week's High
₹11952 Week's Low
₹73.25Book Value
₹34.16Face Value
₹10Mkt Cap (₹ Cr.)
201.08P/E
27.94EPS
3.11Divi. Yield
014 Aug 2023
12:00 AM
AGM
Announcement Date: 14 Aug, 2023
22 May 2024
12:00 AM
Board Meeting
Agenda : Audited Result
| Y/e 31 Mar( In .Cr) | Mar-2023 | Mar-2022 | Mar-2021 | Mar-2020 |
|---|---|---|---|---|
Equity Capital | 23.66 | 23.66 | 23.66 | 57.73 |
Preference Capital | 0 | 0 | 0 | 0 |
Reserves | 49.8 | 38.31 | 33.11 | -6.78 |
Net Worth | 73.46 | 61.97 | 56.77 | 50.95 |
Minority Interest |
| Y/e 31 Mar( In .Cr) | Mar-2022 | Mar-2021 | Mar-2020 | Mar-2018 |
|---|---|---|---|---|
Revenue | 85.14 | 71.21 | 42.47 | 77.2 |
yoy growth (%) | 19.54 | 67.68 | -44.98 | 18.85 |
Raw materials | -39.28 | -36.52 | -19.98 | -38.28 |
As % of sales | 46.13 | 51.28 | 47.05 | 49.58 |
Employee costs | -14.5 | -11.98 | -10.25 | -7.47 |
| Y/e 31 Mar( In .Cr) | Mar-2022 | Mar-2021 | Mar-2020 | Mar-2018 |
|---|---|---|---|---|
Profit before tax | 7.3 | 5.82 | -1.87 | -14.27 |
Depreciation | -5.49 | -4.47 | -3.26 | -3.64 |
Tax paid | 0 | 0 | 0 | -2.17 |
Working capital | -0.75 | 16.58 | 6.23 | -27.03 |
Other operating items |
| Y/e 31 Mar | Mar-2022 | Mar-2021 | Mar-2020 | Mar-2018 |
|---|---|---|---|---|
Growth matrix (%) | ||||
Revenue growth | 19.54 | 67.68 | -44.98 | 18.85 |
Op profit growth | 11.6 | 738.01 | -124.32 | -3.16 |
EBIT growth | 23.33 | -468.5 | -76.13 | -6.25 |
Net profit growth | -11.59 | -123.11 | 53.2 | -10.93 |
| Particulars (Rupees in Crores.) | Mar-2019 | Mar-2018 | Mar-2017 | Mar-2016 | Mar-2015 |
|---|---|---|---|---|---|
Gross Sales | 43.36 | 47.17 | 64.96 | 85.32 | 97.67 |
Excise Duty | 0 | 0 | 0 | 0 | 0 |
Net Sales | 43.36 | 47.17 | 64.96 | 85.32 | 97.67 |
Other Operating Income | 0 | 0 | 0 | 0 | 41.11 |
Other Income | 1.66 | 31.33 | 1.14 | 1.98 | 4.9 |
Company Name | LTP (₹) | P/E (%) | Mkt.Cap (₹Cr.) | NP Qtr (₹Cr.) | Div.Yield (%) | Sales Qtr (₹.Cr) | Book Value (₹) |
|---|---|---|---|---|---|---|---|
Sun Pharmaceuticals Industries Ltd SUNPHARMA | 1,568.65 | 123.31 | 3,76,323.69 | 867.6 | 0.86 | 5,536.99 | 98.75 |
Divis Laboratories Ltd DIVISLAB | 4,519.8 | 76.17 | 1,19,994.45 | 531 | 0.66 | 2,259 | 507.93 |
Cipla Ltd CIPLA | 1,485.5 | 32.29 | 1,19,928.54 | 1,038.4 | 0.57 | 3,444.92 | 346.41 |
Zydus Lifesciences Ltd ZYDUSLIFE | 1,144.45 | 33.51 | 1,15,173.54 | 1,405.2 | 0.26 | 3,172.6 | 156.19 |
Dr Reddys Laboratories Ltd DRREDDY | 6,636 | 25.85 | 1,10,759.07 | 1,034.8 | 0.6 | 5,081.8 | 1,458.96 |
Figures of Market Capital(Mar Cap), Quarterly Net Profit(NP Qtr) and Quarterly Sales(Sales Qtr) are in ₹ Cr.
Non-Exec. & Independent Dir.
Babulal Kamlesh Kumar
Chairperson / Executive Director
Shanmugam Hemalatha
Non-Exec & Non-Independent Dir
Akilapriya Chandrashekar Raju
Non-Exec. & Independent Dir.
Palamadai Krishnan Sundaresan
Non-Exec. & Independent Dir.
Ravichandran Chitra
Non Executive Director
Upendar Mekala Reddy
Independent Director
Krishna Yeachuri
Whole-time Director
Vinayak Dinesh Dendukuri
Company Sec. & Compli. Officer
A Mohanachandran
Tel: -
Website: -
Email: -
Tel: -
Website: -
Email: -
Reports by Bafna Pharmaceuticals Ltd
Summary
Bafna Pharmaceuticals Limited (BPL) was started as a proprietary concern in 1981 by Mr. Bafna Mahaveer Chand in the name of Bafna Pharmaceutical and has been engaged in the business of manufacturing pharmaceutical formulations of Betalactum and Non Betalactum products. The first manufacturing unit was set up at Madhavaram (Chennai) during October 1984 for manufacture of tablets with an installed capacity of 420 lacs tablets p.a. Subsequently the capsule line was added during 1987 with a capacity of 300 lacs capsule p.a. and then liquid line with an installed capacity of 45000 lts p.a was added in 1990. Bafna Pharmaceuticals, incorporated in 1995, had acquired the entire business of the proprietary concern. During the year 2001, the company constructed a separate block at Madhavaram for manufacturing Betalactum products. During 2006, Bafna has set up a 100% EOU unit at Madhavaram for the production of tablets and capsule with a capacity of 6973.20 lacs and 2462.40 lacs. This facility has been set up as per revised Schedule M under the Drugs and Cosmetics Act, 1947. The unit has been WHO GMP certified and also ISO 9000 certified. The manufactured products in this factory catered to the markets of Srilanka, Ghana and Ukraine.Bafna was carrying on contract manufacturing for M/s Croslands Pvt. Ltd, a Mumbai based Pharmaceutical Company during the period 1994 to 2000. The companys first product was registered in Srilanka in 1995 and the company made its first export during the same
Read More
What is the Bafna Pharmaceuticals Ltd share price today?
The Bafna Pharmaceuticals Ltd shares price on N/A is Rs.₹87.49 today.
What is the Market Cap of Bafna Pharmaceuticals Ltd?
Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of Bafna Pharmaceuticals Ltd is ₹206.97 Cr. as of 22 Jul ‘24
What is the PE and PB ratio of Bafna Pharmaceuticals Ltd?
The PE and PB ratios of Bafna Pharmaceuticals Ltd is 27.94 and 2.54 as of 22 Jul ‘24
What is the 52 Week High and Low of Bafna Pharmaceuticals Ltd?
The 52-week high/low is the highest and lowest price at which a Bafna Pharmaceuticals Ltd stock has traded during that given time period (similar to 1 year) and is considered as a technical indicator. The 52 week high and low of Bafna Pharmaceuticals Ltd is ₹73.35 and ₹116.45 as of 22 Jul ‘24
What is the CAGR of Bafna Pharmaceuticals Ltd?
Bafna Pharmaceuticals Ltd's CAGR for 5 Years at 68.43%, 3 Years at -21.68%, 1 Year at -10.65%, 6 Month at -13.51%, 3 Month at 2.53% and 1 Month at 17.29%.
What is the shareholding pattern of Bafna Pharmaceuticals Ltd?
The shareholding pattern of Bafna Pharmaceuticals Ltd is as follows:
Promoters - 88.30 %
Institutions - 0.00 %
Public - 11.70 %
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Securities Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2024, IIFL Securities Ltd. All Rights Reserved
www.indiainfoline.com is part of the IIFL Group, a leading financial services player and a diversified NBFC. The site provides comprehensive and real time information on Indian corporates, sectors, financial markets and economy. On the site we feature industry and political leaders, entrepreneurs, and trend setters. The research, personal finance and market tutorial sections are widely followed by students, academia, corporates and investors among others.
Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
